Skip to content
Innovative Tech
Diseases
Health Policy
HTA
Data Analysis
Clinical Practice
Contributors
BACK TO MAIN SITE
Cost Savings on Generic Drugs: Transparent Pric...
By
HEOR Staff Writer
June 18, 2024
Introduction Through its transparent, online direct-to-consumer pharmacy model, the Mark Cuban Cost Plus Drug Company (MCCPDC) has made substantial progress in the provisi...
Brucellosis Control in Armenia: A Holistic Approach
Introducing GRACE for Patient-Centric Care
Universal Early Parenting Programmes: Unraveling the Cost-Effectiveness
The Economic Burden of Knee Arthroplasty Revisions: A Cost Analysis from Türkiye
Rethinking Health State Valuation: Moving Beyond ‘Dead’ as an Anchor
Advancing Pneumococcal Disease Prevention in Japan with PCV20
The Impact of Time Horizons on QALY Calculations in Healthcare
Making Better Choices in Diabetes Care With Multi-criteria Decision Making (M...
The Power of Real-World Evidence: Bringing Everyday Health Data to Drug Appro...
HTA in Essential Health Benefit Package Design
Healthcare Decision-Making with MCDA Framework: The Saudi Arabian Perspective
Health Technology Assessment in South Africa: Towards NHI
« Previous
1
…
26
27
28
29
30
…
47
Next »